Gilead Moves Into Microbiome In Deal With Second Genome
Gilead lands on Second Genome as its first partner to apply microbiome analysis to pipeline assets to look for biomarkers. Companies also team up on GI drug discovery.
You may also be interested in...
Deal Watch: Alnylam/Dicerna Pact Addresses IP Questions Around Primary Hyperoxaluria Programs
The two RNAi firms cross-license IP from their PH programs, while also partnering on a rare liver disease candidate. GSK invests $250m in Vir and will help to advance its antibody candidates for COVID-19.
Asia Deal Watch: Busy Eikon Partners With Impact On Selective PARP1 Inhibitors
Yuhan and J INTS BIO and Betta and C4 sign deals centered on lung cancer candidates. Viatris’s Japanese affiliate gets in-country rights to InDex’s Phase III ulcerative colitis candidate.
Akero Shows FGF21/GLP-1 Combo’s Potential In NASH And Type 2 Diabetes
Phase IIb data show that Akero’s efruxifermin on top of GLP-1 therapy is relatively safe and offers liver fat reductions and fibrosis improvements in NASH patients with type 2 diabetes.